Conde Diez Susana, de Las Cuevas Allende Ricardo, Conde García Eulogio
Medicina de Familia, Servicio Cántabro de Salud, Santander (Cantabria), España.
Medicina de Familia, Servicio Cántabro de Salud, Centro de Salud Bajo Asón, Ampuero (Cantabria), España.
Med Clin (Barc). 2017 Mar 3;148(5):218-224. doi: 10.1016/j.medcli.2016.10.047. Epub 2017 Jan 7.
Hepcidin is the main regulator of iron metabolism and a pathogenic factor in iron disorders. Hepcidin deficiency causes iron overload, whereas hepcidin excess causes or contributes to the development of iron-restricted anaemia in chronic inflammatory diseases. We know the mechanisms involved in the synthesis of hepcidin and, under physiological conditions, there is a balance between activating signals and inhibitory signals that regulate its synthesis. The former include those related to plasmatic iron level and also those related to chronic inflammatory diseases. The most important inhibitory signals are related to active erythropoiesis and to matriptase-2. Knowing how hepcidin is synthesised has helped design new pharmacological treatments whose main target is the hepcidin. In the near future, there will be effective treatments aimed at correcting the defect of many of these iron metabolism disorders.
铁调素是铁代谢的主要调节因子,也是铁紊乱的致病因素。铁调素缺乏会导致铁过载,而铁调素过量会导致或促成慢性炎症性疾病中铁限制性贫血的发展。我们了解铁调素合成所涉及的机制,在生理条件下,调节其合成的激活信号和抑制信号之间存在平衡。前者包括与血浆铁水平相关的信号以及与慢性炎症性疾病相关的信号。最重要的抑制信号与活跃的红细胞生成和matriptase-2有关。了解铁调素的合成方式有助于设计以铁调素为主要靶点的新药理治疗方法。在不久的将来,将有旨在纠正许多这些铁代谢紊乱缺陷的有效治疗方法。